Starling Oncology, Inc.: Chernett Jorey amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Chernett Jorey filed an amended Schedule 13G with the SEC disclosing a change to its passive stake in Starling Oncology, Inc. under accession number 0001193805-26-001476. The filing updates the investor's previously reported beneficial ownership position in the oncology company. Schedule 13G amendments are typically triggered when a passive holder's ownership crosses the 5% threshold or moves by more than 5% of the class, though the filing summary did not specify the exact stake or percentage change. The disclosure matters because it signals a shift in a significant institutional holder's position in Starling Oncology. Investors should watch for further 13G or 13D filings to confirm whether the change reflects accumulation, dilution, or an exit.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Starling Oncology, Inc., Chernett Jorey